0001140361-23-022716.txt : 20230503 0001140361-23-022716.hdr.sgml : 20230503 20230503161808 ACCESSION NUMBER: 0001140361-23-022716 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230503 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES, INC. CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 23884254 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-1000 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ENTERPRISES INC DATE OF NAME CHANGE: 19980909 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 8-K 1 brhc20052418_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
May 3, 2023
  
 
Date of Report (Date of earliest event reported)
  

 
NU SKIN ENTERPRISES, INC.
  
 
(Exact name of registrant as specified in its charter)
  

Delaware
  
001-12421
  
87-0565309
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
  
 
(Address of principal executive offices and zip code)
  

 
(801) 345-1000
  
 
(Registrant’s telephone number, including area code)
  

 
N/A
  
 
(Former name or former address, if changed since last report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On May 3, 2023, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2023, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Nu Skin Enterprises’ press release dated May 3, 2023, regarding financial results for the three-month period ended March 31, 2023.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ James D. Thomas
  
 
James D. Thomas
 
Chief Financial Officer
   
Date:  May 3, 2023
  

 
 EX-99.1 2 brhc20052418_ex99-1.htm PRESS RELEASE DATED MAY 3, 2023
Exhibit 99.1
 
 

FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports First Quarter 2023 Financial Results

Company Reiterates 2023 Guidance

PROVO, Utah — May 3, 2023 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first quarter 2023 results in line with expectations.

Executive Summary
Q1 2023 vs. Prior-year Quarter

Revenue:
    
$481.5 million; (20)%
•          (4)% FX impact or $(29) million
Earnings Per Share
(EPS):
    
$0.23 or $0.37 excluding restructuring and impairment charges associated with the company’s strategic resource reallocation, compared to $0.76
Customers:
    
1,083,536; (18)%
Paid Affiliates:
    
221,354; (12)%
Sales Leaders:
    
43,755; (17)%

“First quarter results were in line with our guidance reflecting better-than-expected performance in South Korea and Mainland China, while the Americas and Southeast Asia continued to be impacted in large part by macro-economic factors including inflation and recession concerns,” said Ryan Napierski, Nu Skin president and CEO. “Although our results were down due to a difficult comparison and persistent macro-economic challenges, we continue to make steady progress toward the key priorities that underpin our Nu Vision 2025 strategy. During the quarter, we experienced improving sequential trends in customers and paid affiliates in Mainland China. We also introduced ageLOC® TRMe®, our personalized weight management system in South Korea, driving healthy results. In addition, our ageLOC® LumiSpa® iO device continues to gain traction with more than 3.7 million treatments performed to date, while enhancements to the capabilities of our Vera® and Stela apps are driving customer conversion and user engagement.

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 2
“In the second half of this year, we’ll further strengthen our position as the world’s leading beauty device system brand with the introduction of ageLOC WellSpa iO™, our next connected device system focused on holistic wellness and beauty. We will also continue to evolve our social commerce business model to empower our micro- and nano-influencers to scale their businesses and will build on the continued adoption of Vera and Stela to develop deeper connections with our consumers and affiliates. With a dedicated team and a strong foundation, we remain confident in our Nu Vision 2025 strategy and are well positioned to drive long-term sustainable growth and shareholder value.”

Q1 2023 Year-over-year Operating Results

Revenue:
    
$481.5 million compared to $604.9 million
•          (4)% FX impact or $(29) million
Gross Margin:
    
72.3% compared to 73.3%
•          Impacted by global inflationary pressure
•          Nu Skin business was 76.4% compared to 76.5%
Selling Expenses:
    
39.1% compared to 40.1%
•          Nu Skin business was 41.7% compared to 43.0%
G&A Expenses:
    
27.8% compared to 24.6%
Operating Margin:
    
3.3% or 5.4% excluding restructuring and impairment charges, compared to 8.6%
Other Income / (Expense):
    
$(1.5) million compared to $(1.5) million
Income Tax Rate:
    
22.0% compared to 23.6%
EPS:
    
$0.23 or $0.37 excluding restructuring and impairment charges compared to $0.76

Stockholder Value

Dividend Payments:
    
$19.4 million
Stock Repurchases:
    
$0.0 million
•          $175.4 million remaining in authorization

Q2 and Full-year 2023 Outlook

Q2 2023 Revenue:
    
$485 to $525 million; (14) to (6)%
•          Approximately (1) to (2)% FX impact
Q2 2023 EPS:
    
$0.45 to $0.55
2023 Revenue:
    
$2.03 to $2.18 billion; (9)% to (2)%
•          Approximately (1) to (2)% FX impact
2023 EPS:
    
$2.27 to $2.67 or $2.41 to $2.81 non-GAAP

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 3
“We are reiterating our 2023 guidance with gradual sequential improvements in our business throughout the year despite a challenging global macro environment,” said James Thomas, interim chief financial officer. “We are managing our cost structure conservatively and are investing in key growth initiatives that support our Nu Vision 2025 strategy. Our annual revenue guidance remains at $2.03 to $2.18 billion, with an approximate 1 to 2 percent foreign currency headwind. We are also reiterating reported EPS of $2.27 to $2.67 and increasing non-GAAP EPS to $2.41 to $2.81, which excludes the first quarter restructuring charge of $9.8 million. For the second quarter, we project revenue of $485 to $525 million, assuming a negative foreign currency impact of approximately 1 to 2 percent, with reported earnings per share of $0.45 to $0.55.”
 
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 17, 2023.
 
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a global integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people look, feel and live their best with products that combine the best of science, technology and nature. Backed by nearly 40 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in nearly 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company’s strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children’s health, education and economic circumstances throughout the world. For more information, visit nuskin.com.
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro-environment and the company’s performance, growth, shareholder value, strategies, transformation, initiatives, product pipeline and product introductions, digital and social-commerce tools and initiatives, customers, sales leaders, and affiliates; projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “project,” “continue,” “outlook,” “guidance,” “remain,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 4
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 •
risk that epidemics, including COVID-19 and related disruptions, and other crises could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;

•
unpredictable economic conditions and events globally;

•
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

•
continued competitive pressures in the company’s markets.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 5
Earnings per share and operating margin, each excluding restructuring and impairment charges, also are non-GAAP financial measures. Restructuring and impairment charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of restructuring and impairment charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share and operating margin calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended March 31, 2023 and 2022 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
March 31,
          
Constant-
Currency
  
   
2023
    
2022
    
Change
    
Change
  
Nu Skin
                        
Americas
  
$
101,157
    
$
123,580
      
(18
)%
    
(15
)%
South Korea
    
70,324
      
72,133
      
(3
)%
    
3
%
Mainland China
    
67,976
      
124,495
      
(45
)%
    
(41
)%
Southeast Asia/Pacific
    
67,810
      
90,236
      
(25
)%
    
(21
)%
Japan
    
52,606
      
61,791
      
(15
)%
    
(3
)%
EMEA
    
47,444
      
52,968
      
(10
)%
    
(6
)%
Hong Kong/Taiwan
    
34,548
      
38,494
      
(10
)%
    
(5
)%
Nu Skin other
    
(115
)
    
620
      
(119
)%
    
(119
)%
Total Nu Skin
    
441,750
      
564,317
      
(22
)%
    
(17
)%
Rhyz Investments
                                
Manufacturing
    
35,767
      
40,341
      
(11
)%
    
(11
)%
Rhyz other
    
3,945
      
241
      
1537
%
    
1537
%
Total Rhyz Investments
    
39,712
      
40,582
      
(2
)%
    
(2
)%
Total
  
$
481,462
    
$
604,899
      
(20
)%
    
(16
)%

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2023 and 2022:

   
Three Months Ended
March 31,
        
   
2023
    
2022
    
Change
  
Customers
                  
Americas
    
266,378
      
318,458
      
(16
)%
South Korea
    
120,907
      
140,648
      
(14
)%
Mainland China
    
217,101
      
289,060
      
(25
)%
Southeast Asia/Pacific
    
117,266
      
165,657
      
(29
)%
Japan
    
115,161
      
122,616
      
(6
)%
EMEA
    
190,313
      
216,037
      
(12
)%
Hong Kong/Taiwan
    
56,410
      
68,975
      
(18
)%
Total Customers
    
1,083,536
      
1,321,451
      
(18
)%

Paid Affiliates
                  
Americas
    
38,707
      
46,317
      
(16
)%
South Korea
    
40,599
      
49,474
      
(18
)%
Mainland China
    
24,522
      
22,783
      
8
%
Southeast Asia/Pacific
    
36,431
      
43,347
      
(16
)%
Japan
    
37,155
      
38,096
      
(2
)%
EMEA
    
27,654
      
33,914
      
(18
)%
Hong Kong/Taiwan
    
16,286
      
17,928
      
(9
)%
Total Paid Affiliates
    
221,354
      
251,859
      
(12
)%

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 6
Sales Leaders
                  
Americas
    
8,242
      
9,548
      
(14
)%
South Korea
    
6,242
      
6,072
      
3
%
Mainland China(1)
    
10,034
      
14,146
      
(29
)%
Southeast Asia/Pacific
    
6,337
      
8,012
      
(21
)%
Japan
    
5,688
      
5,977
      
(5
)%
EMEA
    
4,524
      
5,455
      
(17
)%
Hong Kong/Taiwan
    
2,688
      
3,253
      
(17
)%
Total Sales Leaders
    
43,755
      
52,463
      
(17
)%

(1)  The March 31, 2023 number reflects a modified Sales Leader definition, as described in our quarterly report on Form 10-Q.
 

 ●
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.


●
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.


●
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
March 31,
  
   
2023
    
2022
  
Revenue
  
$
481,462
    
$
604,899
  
Cost of sales
    
133,588
      
161,499
  
Gross profit
    
347,874
      
443,400
  
                 
Operating expenses:
                
Selling expenses
    
188,124
      
242,699
  
General and administrative expenses
    
133,899
      
148,556
  
Restructuring and impairment expenses
    
9,787
      
—
  
Total operating expenses
    
331,810
      
391,255
  
                 
Operating income
    
16,064
      
52,145
  
Other income (expense), net
    
(1,476
)
    
(1,453
)
                 
Income before provision for income taxes
    
14,588
      
50,692
  
Provision for income taxes
    
3,212
      
11,976
  
                 
Net income
  
$
11,376
    
$
38,716
  
                 
Net income per share:
                
Basic
  
$
0.23
    
$
0.77
  
Diluted
  
$
0.23
    
$
0.76
  
                 
Weighted-average common shares outstanding (000s):
                
Basic
    
49,644
      
49,991
  
Diluted
    
50,058
      
51,066
  

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

             
   
March 31,
2023
    
December 31,
2022
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
229,941
    
$
264,725
  
Current investments
    
16,774
      
13,784
  
Accounts receivable, net
    
60,008
      
47,360
  
Inventories, net
    
366,537
      
346,183
  
Prepaid expenses and other
    
100,302
      
87,816
  
Total current assets
    
773,562
      
759,868
  
                 
Property and equipment, net
    
437,986
      
444,806
  
Operating lease right-of-use assets
    
98,683
      
98,734
  
Goodwill
    
206,432
      
206,432
  
Other intangible assets, net
    
64,711
      
66,701
  
Other assets
    
243,271
      
244,429
  
Total assets
  
$
1,824,645
    
$
1,820,970
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
49,494
    
$
53,963
  
Accrued expenses
    
275,774
      
280,280
  
Current portion of long-term debt
    
47,500
      
25,000
  
Total current liabilities
    
372,768
      
359,243
  
                 
Operating lease liabilities
    
78,776
      
76,540
  
Long-term debt
    
372,609
      
377,466
  
Other liabilities
    
107,522
      
110,425
  
Total liabilities
    
931,675
      
923,674
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
611,483
      
613,278
  
Treasury stock, at cost – 40.7 million and 41.1 million shares
    
(1,559,080
)
    
(1,569,061
)
Accumulated other comprehensive loss
    
(91,005
)
    
(86,509
)
Retained earnings
    
1,931,481
      
1,939,497
  
Total stockholders’ equity
    
892,970
      
897,296
  
Total liabilities and stockholders’ equity
  
$
1,824,645
    
$
$1,820,970
  

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Impact of Restructuring and Impairment
to GAAP Operating Margin
(in thousands, except for per share amounts)

   
Three months ended
March 31,
  
   
2023
    
2022
  
Operating Income
  
$
16,064
    
$
52,145
  
Impact of restructuring and impairment:
                
Restructuring and impairment
    
9,787
      
-
  
Adjusted operating income
  
$
25,851
    
$
52,145
  
                 
Operating margin
    
3.3
%
    
8.6
%
Operating margin, excluding restructuring impact
    
5.4
%
    
8.6
%
                 
Revenue
  
$
481,462
    
$
604,899
  


NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP
Earnings Per Share
(in thousands, except for per share amounts)

   
Three Months Ended
March 31,
  
   
2023
    
2022
  
Net income
  
$
11,376
    
$
38,716
  
Impact of restructuring and impairment expense:
                
Restructuring and impairment
    
9,787
      
-
  
Tax impact
    
(2,593
)
    
-
  
Adjusted net income
  
$
18,570
    
$
38,716
  
                 
Diluted earnings per share
  
$
0.23
    
$
0.76
  
Diluted earnings per share, excluding restructuring impact
  
$
0.37
    
$
0.76
  
                 
Weighted-average common shares outstanding (000)
    
50,058
      
51,066
  

Nu Skin Enterprises Reports First Quarter 2023 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP
Earnings Per Share

   
Year ended December 31,
  
   
2023 - Low-end
    
2023 High-end
  
Earnings Per Share
  
$
2.27
    
$
2.67
  
Impact of restructuring and impairment expense:
                
Restructuring and impairment
    
0.19
      
0.19
  
Tax impact
    
(0.05
)
    
(0.05
)
Adjusted EPS
  
$
2.41
    
$
2.81
  

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
EX-101.SCH 3 nus-20230503.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nus-20230503_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nus-20230503_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 03, 2023
Entity File Number 001-12421
Entity Registrant Name NU SKIN ENTERPRISES, INC.
Entity Central Index Key 0001021561
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 87-0565309
Entity Address, Address Line One 75 West Center Street
Entity Address, City or Town Provo
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84601
City Area Code 801
Local Phone Number 345-1000
Title of 12(b) Security Class A Common Stock, $.001 par value
Trading Symbol NUS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 brhc20052418_8k_htm.xml IDEA: XBRL DOCUMENT 0001021561 2023-05-03 2023-05-03 false 0001021561 NYSE 8-K 2023-05-03 NU SKIN ENTERPRISES, INC. DE 001-12421 87-0565309 75 West Center Street Provo UT 84601 801 345-1000 false false false false Class A Common Stock, $.001 par value NUS false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://nuskin.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - brhc20052418_8k.htm 11 brhc20052418_8k.htm brhc20052418_ex99-1.htm nus-20230503.xsd nus-20230503_lab.xml nus-20230503_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20052418_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc20052418_8k.htm" ] }, "labelLink": { "local": [ "nus-20230503_lab.xml" ] }, "presentationLink": { "local": [ "nus-20230503_pre.xml" ] }, "schema": { "local": [ "nus-20230503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nus", "nsuri": "http://nuskin.com/20230503", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052418_8k.htm", "contextRef": "c20230503to20230503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://nuskin.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052418_8k.htm", "contextRef": "c20230503to20230503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001140361-23-022716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-022716-xbrl.zip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

9Z!XE$B$^2T?P(D+K!*R:B_)WE[NC1?M1PJ+[((DC_OCI)JG_ M3?FDOPY@QJG">W>Q)!C"[Y0EXT:IY51%6\YJGEZ<6+,RWXDP$G3>P9,?APB+#TM[ MQUNA)@F+O$?>:]1_ $>GZ'&:E'U.Z^N?"$G#?&[*\@Y?,\:(J&Z+^#G"X@CA MRA(1=Q$.>0_F4*UU M7+TW+)#A/\S+*KJ*WRX(,2O\G)!\*&KU2,3NQ!+.DZKP_$PT"!/#F H!+6X3]K3^68KC^9->#YYC?!='?<:)QL@[ /,&YZ3N M1<9]!2Y9I$MKG7E%=SG1]&[ 18'H_%Q-!1R$L-XBD N!HJ(S'@YSP/YC=0IE M1BPRZ@P[Y/SJZXL.ETQI#=0/03H0G8QC0CVOD(V\_5S/HVG&>;%H143L!S%,@,@-*QI, "-R=1A' M"P_#@5&D0B)G)$@Z49X"K3IP4X=<-XO&6'0/C%/0U"81F6CTY! M*A?O*D4_/R9T0@7-*0X,?:*;[S8LOW\FO^QQ7;;T=%*9SW5=#K(-3U\-0"]- M6IF 7N/*S:_+\K+KIN@I636]+)E/(:)3I6B2PEL]/D:4-QD?=X$DL="B!<* M!3,. XZJ,?N"%@M'7,+&HY#W:XR_*:3/6"A>%W)A7C:W9()A <&CHKUGJ:?A M,3W>=IZSK;@'>#SU1%-Q!42"-XB 8&6KR(ARTZ!#WH+S50PY A$/:L!4A5&3 M3O4+)<5SLJ!?G"\%-WB#21OWLC2CPJ3T6&SR5%+)5[[=]8O94X*;JR@OL@^O3SX56-]Q71 M:U\A5WD"#X._^OSR>!;7X&L"%3OD9O#X=\&"0?K,B5XU(0U$*A9[,E-13,*J M)J^S"PTTS7G[_M+Z$.\(BF;JE5TWMOO*8203_5+9O1,"!5-4X#HCR+*B_'_< M3I2W37]4:BL_QM3$LDQS6"ZN'&#UBF:EI3(!!!6=Z7DGTEJ#4K!:OA4+#L A M7(F-60RX5U<-M0!3-5 PJ#QA_I!?X]B'/ZOVJH5M"-0M+-RX,OBYJ1WZH"3' M*U!TL%<(']'DL(/J_( I.@2)EP]AL("U.2=!L$IAX8EF]34-J)0ZKHHUY[L\ MZGHL_28*<)40_2[E[N0LZGR-@Z@;UI"SCO?N3Q__,.3 QD& F!B#=V S9X( MO "K".'U$70 __LV TE0U?RODF19Y43RK[PKM6C2!9@+P?$IFB$+]ZQ?#B L M!Y".!R 43RDJAHP*U(+4N2T%D.Y<5J857,K+\S$N"X=#ZQJ&L S!IHI\YBM% MB^7JI]K5@I]>?0>/*0+SJWC&=,0"'FA./U#(1C#Q"L-RH5PM/*%LZLSTLG-U M"+XVR+I+$"ZU&<=B0[DX8J)^M4^ @&"3\I"[."%%.)ZE6[Z<@)7/SR73*$]& M<5H<,-%G/JB>0MF+N[DK6%$AI ]IY:-RL:^ 9"[>%\4S?27# "2R$,C*S' G M#L*8%E,T2,;\)Q:W."QE$JT8J[!9@M8.K5%*9:+,-Y%6Q@J-VUY"[-?$8$TU M*)5@)Z-@Q(3>%@>=E!?K3@M?C'N+9[%<5C1L/:N\6DJ M,#YQ.E98G(ZES/3P?E6YX3.D*IUR19 R$G9E/.X/$HA]T,H"[UF9=\S[(0\2 MT')>>36]Q-,4*/CYU82CQIP@ @6C8BKBV)KPL=CB M-_:+^.CN8K@HCFU)^6YNCXK9/<:Y<,Y$5_*@_\AO3UG]!:".9]D?5* _T?DE M1L3X[MDX"E9>+GAR]BHW^+Q@Q$]MF?FF7)?9RU5C]]GK<5&Q/'NYBE#-7B\" M5M75:0*7MW#?^O-#6G!Q2!_G+G%)/;[(EV,,D0+L M0YH4UTLET5F8PMZJQASS7YC_POP7YK^:RG^9TN:_]NN%/!$+?L)6+\[F"\6) M(W6='T3%&2S A-^*NW)^C JW_2?GV0EM!:H>+!'" P@BLU,.5,!=,Z^X2,KFOYCF&KM--UN)! ; )F61X[K"%5Y, M\RQ>\N)5RGZ>*G7:2%IQEBUPQ$9@*@\#+ZU'Q-Y]^=>'7RZT[A1$_2!-\E'I M $Q,.Z_0%04>*TLPG&3R:OGIN=S;PH5;M71J#8#T=,UCCJKW_9YC^JK3Z]J: M:ZN.2XV^87@> @0!,@T0ZO/#,1D9Y3VXP),B%0RJ$SAGP@P5CX_C P)0/OCO MR2-7(5S)A(".D-#22X\3\9"0JPOAEBX,LPNOOR^BQ? # ;D&<=0S];ZJ6[:C MVB9SG:YN]OK4,*V>9C.MWT,<(8Z6*1H_2'B92%HVN!_'#!-VEU=9<[Z5?1+E MF<5"F>>J*RI^VY^1,*A$%#I=>!#UD#[R[/DP!@,PX''8H'!R&/]=S(^]%0 3 M)TW361(0'IF,BA!K-K8Q10*NC'H4(>#T.I,B24C6+K*KX.1(*FZ"2GC51Q^>6-2>Y-)\9KJO9OMO73,/J MNXYN^K9F]73/M_M]BI(+)=>,!<"]0AJ$>5%,5N5E>%XDY )A*E(O+H_+'6)R MQR*1J2^PR:L=Z#"N*HB>4/%<:$V?H#Y^4CH"),7C9G>5')W G-<$+9!>99:: MEU'0-&@.@7[?<'1&-693V[29V;6MGL5,Z-J_SB2-Q:'FS&8JAYMP*_ M47%J5%A9((UAB/:ZIF.H9M]V?1,6UJ6ZX6F>J^J.UG<8^K&(H1D,3>#Q6$L+ M#QG+QCU4 V]29% P_1T_E+C(JH^MPSF03!71CFWA(?.# C_5<=.$ESH$P_*0 MZ!F@Q=,;&.:U5XG2:GRE^=T8 +N&VK=KEF=:7:]G@3WI,,W75,WL\10< M A !..< I**BX6%A0,2E>J;X5%2B%6SR.I"ZN)A^[E[,*KLC$UU_3&&Q4 M6^N:U.FQGLL )E[/UQW5IP:8@/#1MQ V")ME>HM[-M.U7_U<;!R;%!O52KRJ MV%&%"C95O4P&O!K/^RL/$N8WA@93U_L:=?NZP9AI6F[/-TW/L@RCY].>[;J( M!D3#O!))ZQD(ZH&F*';&C8"5N0D7W2G$9WPCAH@1\')N#I^R26B:\YV9?)<$ MW[P'J"HB!OVIJ$55TB"C%W$ M_7Y*@JDH+^$VYP77DGS'4PI3&?*'BVKZ<74E3YF4P58>,%UUG(TAW65=E9J6 MJC'+-EU#==6>#AAGI@,JT+$-1#HB?0;ID\A&658R;]7-ESB/,X[%/J,B%Y\P MH>>F0 8@%UF01X$?8+Y@*" 31(.@%V3B:KE#IMQ[(K96)Z2J5YW$'6LESXN3 M)CQ44H%\?"\'=L:2H0A(PAOXID;A-/(R]7+;$Q_/M&P(>"&P@)W8@G,'2&') M](-A$(2[F2 1RWR-*!WFVXB!LN*W==H6M!DVFI/P'0H&,6_HZSJFHZH]Q_*Z MKF/W#(_IK(O2 :7#G%5<:GO!9-56+PY./Y@XDD6JK=S6%CXVQM^.3L'*[5.] M#TK0M6C/-5S/H1Y3^PXU^B;R-_+W-'\O4FZEMY?1[Q?"WBLB]F.#[Y5(.X,: M2/F^#+$)(0'QGM4N5 :JR-K[>6'Y@OJ@2<#MT"5QEK=@ M;A)E%,'B&=S#!.-\/#SQPN9T71<&1;M=0^V:7J_; X/8]BSF:?U>U]$Q^X>R M8$865!:G+_B:<8]5;-QG:0KR8"G3E\S>V2FC/[E%8YV-O__)4[XK;>]5]W-" M=&&LK(HZ/U'\7NZY'=>\BSKV?IZ(/-%?.8R#5U253248W!K66U+X0>KE:5I6 M"M5_'7EZ\M\\?-%,4.7& :CMP^1S&NW#?\0W_XGW%;OLG M)C9Y]\*@>K'9EJ>V2MGM\QJ,LN&4:.4PV1G]0-.ROQ+?J1]46XZ[)3%][&]_7/5/6NRA^D3T)$+E17WKT^)D+E;YP#Y#@QSOIU^DONI M>F652R4ZNXR;>DVP.BR&554>#N/[,IP]Z9(UE44"QIA+,[$*&Z)QB-ASDC"^ M!Q84-KCY104$"(4@]B^R^*+X5)Z;&:2B>&]A->:T9*U)E0[Y(/Q\4")>7@0L M>[5\5E4$5993%>\;XZXB#,TF[8THZ"1:,'1M)GRRK-_G3%_KSE3S]D?PX*0X M"ZB<5"GNJJ.QB]]049J5\]WX<1E1F/G=[."FNN),DZ'<,SS>HO3\NNA MB+643:1XN29O%U#6?]&(AH\\(-ICQ6:G.?'#1&1$,,90U)[1_([-LLF3V<XK,_7;:@EL^4=QUC+N.UU1U MN.L8=QTO6H6-=AU;K=IU? @7Z&J^'ZBH;AN7?!:RBK<^&3=*7?5,<:7HT%7L MYYTUV2:D*6VWM,-9]?F#RJOMP6"79)7%%4>BQTF]!@Z^X?5RM:XHDQYH]5Y] MTX9(40FTW, L7K^^*2),TLKT*HR-"0%@J"L=T3XV1%FZB1TZ;7I>%QY1R@H# M*.$A2Q.5CV LX&"6,70WC4H%RXE(@^5^03;\!(#*UH/BJ( M"1]T\4N!N)*-B_Z]Y7ON"C?W_,_.;8?X_ 3*I.9D")\WSE-X5OIB=JO\IA[L M:NI^4QW_;-1Q6NN7E7)=J]O3F45MC9F.VZ6JZ9NLJ^N\,,CL32J\O7XFAK]> MZ/)>C.?GL\+6',]M>;BQ/J&2*/6C.EX]%NQS!S'DFY6.69)#,#LE<_A82WK6;)ME@M0QA?.?3()PZ]%&PGP-QZYR_M M=#!CM*]Q!,_LFD3Q0T)'W*?@_WNVW,K?THPVX9LD(YRC4*&LO&>2R,TP17=BWB8;TM?!+WV*)%F7UD&M78O?^1@WQ6/;VM:MY\"GM:R M#@Z$.&%D'ROO(ZO)Q&K]$QFRT^(U*7D+>4ER7CJ =;B?(Z87 MIX*V6*8U\=,T5&3RMIN48[@.N ZX#K@..UR'0T1,JC(!_<>%Y2KOWEU=O7^_ M<]59U@H5Y[N+6O&S-]797H=3G>/,U=-SWQ,C;V%W;35N7CQ7C'J+8O>S-S\< M<)T6U*:4).AN1((H'^Z IJJ*9KE2&61;\49!W'W$'.(N2TPIQN*Y:J(.<3< MZIC;*VWEQ,FYYAX?1K:BR(L?T;!$P&T*N$W.FNQOGV8#\'B>,-B*=I!9!,LN9_6IO1U4,W914=$ABR2+KRLFZNJ(9)B,TI(Z:@TG+>;/@L!@RP89-F;AK8=I>O8 MDDHC#/XC3.2 B::;BMD]PM CX@1QLDN'SSQ"C+31&43 '07@-DR2F=IIH1"3 M9!LDR1A-,W*9!O2G:^H%_<##J-7)1*U6\0M=3=:B,$F,6F1=*5FWJRJZ(6M( M UD76?<)PTV7U7TZ1A\)0=">A-FY+JM+@WZ+%#FS_Z:P!!AJP5#+WI2SI2NV M*JM=B2D A(D<,+$UQ>G*JJP1)@@3.6!R#:![@-'^Y^.S&_7N=Y8D] M),X&+&E&9AWR"*P=\?,:YV-)*+0V'?VNC 5YRVDV.=)K.SL!(8>0VSOD;%U: M^URZ QE;C9)U1BP%,-89\,[43_>8P-!*-Q61U3YD;>B4GA#[Y.U-04QY+60,8D#^)$"IQ8MJD8&A[XB#A! MG#S=_D(_/HRTTLM$P!T#X#;U.X]04YV*\WD0#_-F\/@W^1#=LS0;LBAKYN1U MJ061S-+F69&RUM!POQ1R&G(:+ +P@1ALMM:O./#"*9*$' M2Y6< M& J/*572V,8QD3[!76.XA>4P6U@,I2OO>:6XB05Q(@E.='G=3D0);D@YZ%8O MS3*D#54>?*L7[O1"8.W5C3PEM&U&H?8XD'+L_I*B0F]M^D@MW)ZU3EL;4=O# MQ';DN7851Y-V2\".N%L&>QU!B:!<(T%KN0A*!.6^)R,%#G=H.Z1S6WV"RQ3,B/$W<^BO M4>GLS>O>Y!G3;UWFI?XG3[.@_[AJHKJV).+" ^-\^1+6,1G2D#NO P;?A&'\ M )0G8NQDE,3W@0_/"Z(^OR\+X@B6 2B>1.(N^ UP:(\E).Z3=S"B>,B25"'7 M-/#)9;\?A '-X/'31T;!YN)/)'&>P,,25G5+);T\#2*6IC".9$)0 M_I)LD#!V,82!#\B()4'LIX1%/O/))YIX V)H"M%5W1 O@@_ZR^5$7(OX!1TX MAP'K>3#GG\_4,_%WR:/B[]6$^OQ*S(.CBN@4IN@$%*K*MY0'_L]G?_NVP1RU MK^N>J9N:S5SJP_^;?>;V^K[>]>K@$,,_6\"=Q>1V'H197-2_B:Q=)B4.69>U M; SKE,K:J\>=/!;!<+<%="\.?0%G0 SYQ!&3DBL.E47"[$"#&8-T]PIG=?TB M71FO#*P\)PPG[]<;[Z:QPQ4[1 1Z!\)O51HVRE)+!KDJBZTE/O4]B<\9 26, M!ZFLX;U+*V2U9EB-6Z?(:T=P,:W;%CY;4#:/2]E(S/+E+E-!\NW'E0.;M@>P7V_C M/!N0W^.$43PU9M7!R2 \]BLA-%U5NJJL33 D49?(NW+RKJDJMBFK%8B\B[S[ ME&5FMI1OC]#\:C:R^(D&4ZY+FN;D1.TQ)H--?XW!6)C MA!$]PCT:>9:BV1AA1)P@3IZNN] 5^QBKLQ GB)-=&J]'")$C-&L/8+M>?;JZ MQ' BNK5C#=I5%4.3JW,#AF20=U>KP[ 55=JCYY!WD7>?JER4JX<)AA.GK5#> MZ5)7387HA@O_6-:+9>VI]FZR_19'=^1W^.>GKS1XD"?RN#*)9)9 *\YKICD- M3*ML3#/5$55F<7:0B>Y&-EJV8FHM*AO;%@C-!WT0R@CE_1S0X"I=IT75;0CE M-D&Y=0>V[WY:N_)&9-W_MT>,'J,C0"N^YP[[DUS,K='S M4D)IMNGH=Q2Z5E374"Q#VMR6S(8#8N7$L&+HFF):TI84(5::HJ84\$"3=TLL M-&#,5I]>[^J<)@F/"NK[MJU97<;ZAFZ:CMGML2[MZ9YK]2GS^[WZ4ASXJ*!# MF/4SIU!AA^V#RX4F=2 NP@DM0J6'CG =FL\F8X=MR0UFK"=>KW.PJSC2MCO$ MLGN$B1PP,6W%T! F"!.$"?;7;G]V$?MK8[7T,N&Q9T6J*E:WK?T7L-#_I%FW MJYA.6[L4(^N>,NO*FR([0>,+NVNC-[ACVLKI#>JF8DEVP#<&31 FTL%$5QQ7 MUGW["!.$B1PPD=6";2JR**5MBXVUI9$O,@N1/>>T;<4T9*V/ED1K(NM*R;JF MH1BFK'EF9%UDW3;F?C'&B&VUT1D\*F?0Y5N[*J980) MPD0.F)P?89+J"(U:;*J-3NVA&Q,[BFUAS1>R;OM8US"4KH:LBZS;/M;% HBZKBF&M.%KJ6T'1,II(<72%->2 M5M$C4IJBIA3@:**GMK0E$2TQ9ZM/.^NIS7]7SNSMS?7[:WK'WB:,?KN$?\8D M]D)&$T&VP3A<#I9Q1?#R2D6ZN>[3]<%-]]">>?/[. 8@PWAG*+-TE.,1CN#* M18]?NJ!]>,9+0L,'^IC.F.*O!PFP43J@/N-\)#Z,GU%,XR4Q1]^)"LL_U>^[ M4B7E-?45&93V..>4N5;A"RILJJ_JQ%PRU55H]1N#L2WWX*( M7$7 =*,D2.%'-VP4)UE*W@=)FI$_A&]..X)?;2R:Y)ACG??Z;'_HS0G!.&TA\WT'-M4W<- M0],UW30TM:=YU/&I37W351W7K6NI(SQNX):&<-='(?GPL('#&TQ-.@>X"">T M")6!?H3KT'R=#1XV('DD ?=9K-?"1=%-:>,*N!L)42(%2KJ*9;:H*@11@BAI MY*@!:?.:N&D/CQJ01J[(+#SV*R%LB:U-290EWC7%G;&._5 M\)+2[I+JE($T'TU1<9R"AB9)8C^PX'&0;VA$?.;1_GNHHJ[482Y%SDW*<,M+8>('.$5AB>9H#> MX#%[@Y9BNUCQA2A!E#R-DJXCJQN$*$&4R(&2\R,\%><(35H\RP!=VD.?+:E8 MNJP);$F4)'*NE)QK*::TA[TAYR+G/K5+15:/Y01M+CS) 'LF8_MS:=J?Z^V* M>F+WM5=IS#*3U1? @@Q8=9-!0:[]VMYS& MYNQ;P- T%$?:^)_4E@,"Y:2 8NF*:4MKB"-0FJ*F%-A @Q!3O(T_B MB+R'$<#(+O[H+)_X/,$J5&[0U%PT&]=]LZ_[GL-ZFF/JGD-MW==)O[16A"2,C^#N.4O(PB,F WL.%'.!"4V!T/T@ (<#@_20>D@R@]"X> M@H!Z)'Z> >*2]D@80P@%&6#E+#(A]\!6N*^^-*G&0.\^##KC/D=\@5P4XVB M!&(*WWMA[L,S6/$W_);C*Q5@[,>@NL3@AH!*DN8 93I+##(>M%(^C8]NYL@] MPON19(,X+1X'\ V!UGRP4RZM0GIYQ@N,,E99/ MHB.%!%Y#K-"NJ9J^ZSE]RS>UOM=CGJZJGL$LNZ)/OA39] (;C__L$YD'-3K<14@3N&$TBD#'%G1[((Q:EE&OI.:%T(802 M%W!!#++G0T0HO+1\TY FWQAH_QY+ U#M\Q)E[MV,FPP@MK)X=M0@X-B(B[XH MFYH!S*\DT2P-*AH!I&B>\O&R("&C)(!A@3T1 T2#E+]I!#(E!AG*7],3#^'_ MA:M^SFT7F&>RGM&C MINIH7=WD'[0N2AZ4/ )64XJ[+G=F90#8-0D_P*@"/[\8/B.:"B2SX2B,'UEI M/M217DB0PH!9**FH-PC8/<@J#\@$WY%N+A*V%\YF Y#>-8"\3.QH>!U M_".#QQ4#K[XH'1 YT+W$L_,8/V]K6\>N3$!\_I/<_O[A,[GZ_/7JYOKFP^W5 MK4(^?'[WA+.UM[&\ V.0A_6X74MN,_@?L9!\;3Y$H)88.?\SHF"(PO2S*"NSS? MYY !TF5C6">Z;J^>$-VI6/@JO.%/A3=\Q;WAQ>?B'60PX\#7[L.@JT<]=QCV M/T2B?0=06C5RW"C6E@QRU?.]U@*COB\H+6:T95@-.DZNO M4[GW8C/-,!1+WOV, M6'R)2)$%*388M?(JV!9[THN&?DCW^MG- /,GF4;GN=@.=PVMK>>'N8 MV(YV,IN.XCJR=LG:%7O+H. 1E8C*E<-@IJ&8JGK:J#RP,8&=RUK?N6POF43L MD8><=G2<=L0ISR\CEM",U\6S[[Q4GJ4O,?UYJ%2,5%UH5K;5I$%S"UP;Y&KD MZL:Y^N"NP4YUU,)#,6&Z=9V%?>R/RE[<+G_@NHJ&G>R1=UO(N[JI*[:TN:]V MJ)]F3P/\E47@4(5B-R#UAT$4I!EWL.Y9L\H*+=&#BHG&8N&\SN24RM,0)XB3 MC7!BNHIEV2>#DSTHX0-7;1;5E+ M0^XE!9U,SC4:\FC(2QJZ0O<4N1JY6CIO.8WDP4(_U8W[P9A+?!RD_"0K^ MK-S)C'['W8Y'EB+9LHY=XK:BDF@G9%TI6==2%;LK:_/Z=JB@QFL\K^524EA/ MU@[S5=YZ,D779!5)6..)F#Q%3&J:TFU7/N,(7%LTS5MNFDL3YY%$#2&G(:=) M(5OG-(9Y8)_M,\L:K?A<=_XR W>9V>3'.3^A?,.I'=]A;?N@TLZL2Z,]UN6& MI&K:Y4.((\0;#.JXBJ.=.,31@42S_K3,>N0TY+3C=" ;\17)B"4D'="$X0$1 M6&+6#CRWP%-"KD:N;IRKVUTXN:@/Z%N:!A[62:YO)AY'-&*_\02UH\NZTT<2 MM88@. $0.+*VMVV'%FSVG(I?@C#/F(^NW*&,WN.0*8W%\"76N>AE(N".$7#R M9L7;[P"C'8XY"_3XD--.@-..UJTZ>_,_C*\F\R\H#)/>,2#0 MI1F->'4'.5=5-7V!J3-,,K0#[.C4(%Q35E;-TNB MC)!U967=;E<[+M8]6G\*TU1H8#;2=V;/&.:WER_OZ9W[&W"Z+=+^&=,&R]D-!'S M'8S5(VCLBE+EE8(B\MUO];%6&PO+ M:^HK,A!1U[+32K78Q7;#A7Q0?54GYI*IKD*KWQB,/9F9GF *PAD*.,T+HKN? MS]0S\7>YO4_\74Q%?%P-=?.6V>RDIH8Z \(YN,\9BA54I^=MJ9U%CUN%X1?] M8ENSL'@+__5+$F3P4X]O3,G)[;<@(E<1,-TH"5+XT0T;Q4F6DO=!DF;DCYPF M\!W15=V 2Q&-O("&<%.:A]G"]G2+<%J_/B?EMB3? CF_"44WHA_'+7&63G9- M,LSY)-/,-RLTYX3AO&A<0"*/\;5>E5]JF!$7'DJIT8M#G_//G^3V]P^?R=7G MKUBS18%3X>\I2%P*B.W \: E\__C&CN!_#- MB_V.[.S-^9^=VP[QXS"D24H 6]D@SE,:^>D3KUY+YZTF)3<5C?.2Y4EA20+_ MY[._J:9[7<E_H&" ZS;C&(X9\M, J*R>W<"U]\6M%> M3<]#GEJR&A'6.==#;SS5L,E!&[B@I[&@APC<[4YD2,M0:_+/JB'*G6KT3S3Q M!L30E,56U$'&P.W>W7OK\HE"9-0MF.07YK%A#[RDQGEU#UV7CU7*[SKOLFA% M+F]OK[[>'B#:MV1)=H[4)>-9C> 2620[%:&X2%(M4OMDQ]F;=WF2@"H@,$66 MI=L4N"(S2L6,N$@M6*23*@9Y1],!H9%///Z!_94',"^0/0V=-7.*>>^M,LBX MJ5+7NTK7E+4@#6M-$'-'B#G;5!S=.AG,'=^.A,K%"*)[EF;#QC2^U")&YIJU M_0)G*4D81X#=[07,H5$+$./%"NQ M]R8U;%515=RP@#!!F#RY^<]1#%L]&9@!N^:MJ*YLK8S;8?Z6?O<[?VKJ^N$C6C@$_9]Q"*^'XFG M*N-LP!(YSEG=\&1R*83%\\64K;6.]S"Q'06G5%4QU#W49>Z&(W;$WDT?C8JH M1%2N@TK74=SV'&:Z'U >DZNKN<)X^!IG-"3>5#$E^KOH,U2P=QQ#L6Q9E;$D MRA5Y5T[>M;J*:\N:L&B'#GK2M<7$"29.3J;C+G(U_(Q',(A' M$?3D6S-&O$X3TW9H"D[GY U'Z;JRAB\DT4C(NW+RKFDJKGIDO"N3&[-CE?0% M%!+-^.$[(:,I*]CE(NY?Y/!'@Q$V-#@/*A0:B]1W7<66-LN/?AG"1!J8.(:L M>R#0T9M=KE_CV'\(PA"].K2,QUML55LQ#4Q.(>\B[TK!N\?LU?&"2A)$&8WN M MY.NO#D<-<=VJE[WG5G*HZ&K5L0)@B3)V%B*XYZ.C"18=O#GG1LDR'20S9O M/E IM-S28M/1[\@(-PU%=Z25&M*=ZH!(.5VDF(JI=T\ *4UK5K/!#853FP)D MTL//$:6-@L>/G<1]4VM&.1,753<4VI6WFN".X-&U#(,H1YPZ#\H,GBC$/UO(\F#3E\9+H->0TY#0I9.L!W4CQ_?'[[^&Q.HF!EJ M!>Y;X%0A5R-7-\[5;:\VK8Y^" /:"\(@"]A61\RA+8FV)'HMR&GMY+3C]5J> M.EEA1!_YL0KHFAS*B#N6"'=3;>>[BMD]G?U,"#F$7-.0LPRE:Y_.3MMV.W5+ ME'V2LTGK;'3QCLKPWJ[BS;'P?#_DW7;RKJLJ\-_CXMVF"S.;/^FABDJ.8IA+ M')&X3\(81@A0&Q*?]1K:B(BMY5N1J)"VM;SI*)8JJ[#"\QX0E*<(2MU2U%,' MY3$YO O/>ZBE-]'U1?=A?%".8MJR6G^M]^D.V1"T:?<. M>QW*EA7?K^C05$>Q=%E;\V-74$2*-$C15,746],6K\5=09LL/ITJ'9%2&;?7 MJ,?"MH.?^V9HBNVT2F:UP*M&5"(JMT*E;@ J9=UM=:SUIIAD:GF229HB!4GT M$'(:8TY::RV_EMIU6.:&J4/D MZI/@:G02T'0[+=,-.0TY#9V$+9V$VRSVO@WBT&=)6C7?9W_E0?;83&-C-*8. M"ETTIM!%0*X^$:YN]_ZN@HA!Y+,H>TDN>.NKA?4([S@YR"60:#B,(W@=*#@B M5)OVBEBJ2N %(6^3E0YH J^@>3:($YB"KY ?U(ZJ:F1$$TZ%G"FDJW;LV5\$ M:9HS'[>4'96-NEV:4M:SPB71?\BVR+8GX:^ M'_!ND#0$=1;X\ OBT5&0T1#].K2 ]R92;$U33%?6/COH*2).9,&)H>B.K+W4 MT/?<3.E^31A-\^2Q\#H50C.@5IJ-W4]3[3AC;Y+79)A:1YMQ+]&O1 .]DA+G MFF)9745M;<_VK6;_ J& 4*A#P08HV&WU60\ !?1_:_ZOY^7#/*09\TDL]HM[ M\7"4L &+TN">D3!.L0@2+?P]"JRNIJBJM!O*-K?P6ZC3$7,G@CG75JQC[()T MA,;# 3K%K&HKW+",!A$_\(\F$8Q)HBWLDHLG[)*Q.2PUA>\Y-UU9'1KL*(-8 MD0DK_"!KYP2P(H,BEJ*G3+JT-ED>_=Q>SP*;61S:.W&[NM)U9 WE8XL91.5I MHM)1]*ZT'6&/LL7,W*S,/3C_*S6K$UEXV0T-LZW.C1_GO9 ].?Z)=-H*Q3\< M<*4VDG0KD&)7KI*KFXIM2IMY6(>[FS8F$'F(O-4IP:&GMLG$WP)Z,Q9#]0DN M4Z#V^!M.P#?D=6]R[S1M!('+E[Z]N7Y_3>_8VX31;Y?PSWCV7LAH(F8T&.MU M,#(J6I17JEF)B_6UK*]B10U5%24;TV]^'\< Z;,WL^NW=)3C$8[@RD6/7[J@ M?7C&2T+#!_J8SE@UKP<)K' ZH#[C2RP^C)]13$.L"E&YF5N+O8BKBXVK8FCLZVK< X/6^+[P9<5$LZ2Z?9T2W^Q;;V M;/$6_NN7A._C"#QXT>>$X;QH7$ BC_&UGH? VA@2%QY**=(#]X?STY_D]O#,P+WAO?V$3B/IF<^/A)R$YR]=T+!+,"KQE\NOEY?7<9 X[MK,WYT"_;!#G M*9 H50C[[K%1!O M[?O440W'9H9M^%V_;K>)X9\M,,V*R6T1UAD&OA^R!7-:7,JQB4^TS(8]9+IW MV;3728':JP>S]BIRJ0OC_O]A$3X%>XF:W5.$ Z:IZD+^VX"]@ M+[E.))-6GBY=ZOUTWMMDA>M'V'^(O'C(L%K^4-7R3ZWN9FLI46!\/ZGUSP&GIBB9OYECRLI=5+(S#F!&3X&U8<2-.Z5!)5B9R&G":+W-_W+HN- @I3%9+=S$#J*H[;JKUD+7!,$:@(U)T#]>*T02J!H;+)UHS-UOK2_T^>BGY- MXRAXT& 4O/6UX+R.M"Q^GEJ)$X^W;4>D/:2;8N&([>DV68*/ MNGA"4GO5=#7%M.5J6H#)640R(GE="MDP K?;HM/V]I9DKCXMZGZ[6C.ZY0WU M-OT=MHQS3^1:;"UA2T:]U_,9 MHQ[K.IJI.HQ:3M_3#,OK=3VUWYL2)MB2$5LRSK1D_!2+EHQ7V)*Q12W$L"7C M4R*G+2WSL"4C\A>V9)1!GK:B)>-GEC6Z#;6U.^BQW]N*T9PFFS%JBN&TJ'Y MMIX7"$X$Y_X*^%W%T4X'G,>Z<6>U9HR$?1^Q*&78E!'K-&2JTT!.0TX[H8H@ M[+^()JYD9>;8)A&]0X1.VZ C;>/"(_#;EJ3 MU/JP\13RN+%QU' N>5WJM$DZ5?4@98?0#:=V(FFN?9!NGVEJ5[$_]3:HI%O&"<&F#ZCZL4EXRDWW&&_82R9'669#7RMLP M[+?MBN"99/MUIQ$QB!A$S&EYKO\C>L4P_X+"&.D=@\<,AW%4.*\IB?,LS6@D MW-=S556;*55MN0$N<6YL]_:QI2JJY1Z7A8S\?,+\K"FJ?=P>7_5II]V"R\&\ MO;E^?PUZY6W"Z+=+^&=, "]D-!&3&HSW,67QJ")'>:4J6RI?.AET?7#3[5!G MWOP^C@%4,-Z9)5PZRO$(1W#EHL$#?4QG5//K00*+# K39WR5 MQ8?Q,XIIB+(KHO+2J_I8JU*W\IKZB@S*UFV\R'VNH^:"JJWJJSHQETQU%5K] MQF#LR.57BE=A8];A6&7_2+YXRR MU6C ?_V2!!G\U.,=WG)R^RV(R!5O!#A*@A1^=,-&<9*EY'V0I!GY(Z<)?"0$/>)#H/LW1Q_]9YG-:OSXFR+8L M_YEVR3-"5:?FA[3 M&.UZ;MTF:773\97-U]9WJMV\+?GVG6K_#48,8;P%.?F%>6S8 P3MI??W%L:W MM-L1L1GXKB#0<+-F@UR0C_'#!0#A6#D?&4T.1OL-+ATSGTE1.G_8O=W/F9]K M+2[VFL)=F3(VL]([NJPU:RW8:(W01&CN$9KVZ4#S6*L"L$7X*2=1I:GHD41A M(JB$]&Y/3HEL#3D:CI^=7TKAUC#!L,GFB]K68-A MO6-J;9'$V&L<10&*@CV* O?$1<$A]B[NI?YR:@#_(/!_C;R9K#_WZ>T@ALW_ M;T>[9=Y]^?SU\MW7VY?KC&2=-^O%>O-+2[G]N>?5*&^9"BG^^V)F0E&<#&D( M[_K$_("^!-+RK]^\SK=\^>*7#/E+_F^4I]^"J./%P^IM/VW[NO7FJI!S5]5> M$,.T+FRCZXR'<2R+^2&Z9VD6)^F^%S0H7Y2P4.R$2^5:7,-R6K2XE8R:D7:$ M+)["'E]9OG!?U*K-;.$F]%+]%RIDK.XWW62^2"M-Y19HGL7C2TGQDN):86=Q MYHK8/E9Y?ETGGVN?GGKMY#'BUDW;"[S^J1?[C^+#(!N&\.'_ U!+ P04 M" !#@J-610Q;,D0# P#P $ &YUY(W"B\N6V76U^TI,!%K@' ()^1S+ M+S#'HH (3YV%E,7$]VDI7@CU$,O]*(CB8!3$2DV&/Y+4YAFLO88WRN2(+0__GY\9L):[$JRO&(%2PC]&6+=#7C MF:6-?6V>08$;!3OX6D0X'H]]8VV@BH@&;:#D'>:M/)79UV;M M$[A!Z$:AHWH$ -TED%(FH50-:9;JQ:(@-&7UBEK3%9W877C&*3 UGFC6J2-( M7F2Z@&9MP7$Z==1>NW:3?Q4<>TJI17"6X2,[HLV^$$M-(@;H*@@"XP#*TAY FH*(# M+;XKOTO2Y2\%3I[HM1EWNZ/VKB''/!',4)F=X;A1=MBO7K5;8 ^4WSE1U<+V MN=.G3C4Q=L=?'QYD4=D5W>-0#0?$%@3UB6SA>M O:O?F'E>W)<5S_1+;'[[KEG&^Y>5J M'C>,W/#]%S_;D^48!!Z[ 7;G#IAD&_JN\\-T^,:AUTX-')(0\]6@=\70S-T&-7OXF4 M/B1=O"HR2*%D?'VOYJI3GXEW!N]*'; ML^]_XJ"8OWF:N=@(,8^CBNSZ#U!+ P04 " !#@J-6-2?!GW\( !T6 M% &YU&ULS9Q=;]LV%(;O!^P_<-[-!M1V+6_# M$C0NLK0I@J5)D*38%X9"EFE'F"P&E-PX_WZD)-HB>4@I%27KIG5XWO/RZSF2 MK$1Z\W:[CM 73).0Q">#R>CU .$X((LP7IT,-LG03X(P'+R=??O-F^^&PP\X MQM1/\0+-G]%OE/@+&BY6&-W<7B_#""-O.IJ.O-'/DY]^+86'0YX>A?%_Q_R? MN9]@Q+J-D^-M$IX,'M+T\7@\?GIZ&CU-1X2NQM[KUY/QGQ\O[X('O/:'89RD M?AS@ 6+ZXR1KO"2!GV9C+J5OYS02!M/QKB^C@O\T%+(A;QI.O.%T,MHFBT$Q M1!ZNT8F0;S5],:?)T='1.(ONI,PHM%COILU6#Z%\_2B)\"U>(O[_I]L+8_;1 MF"O&,4XO_3F.6)=9>OK\B$\&2;A^C+!H>Z!X"?M$E.YL^.H<\=69_,)7Y_N] M\[C)\%8H7;U,<+_!"],R]+I<,HF<3( 8VF8\K$KL;$\4)XO#97BA&QH@)4>M!%\CN;1BQ9) MVN-\:";3=<2ZY1<&.!Y^NAN@<&'2SK(F](]H_/?->#]J?::G5-X7GP9B2.QC MQ30*Q3@@[&3YF ZE&2TI69OV@50L7[$:F=\QDF0H)8F(LTYLR*$Y-AA&;7O&JFY MR#*UH%S@:_%JG^,[$H5!F++OLQ_9!0<-_4A!RBPHI@@)&N"KV[EBU^AL M>0 M,-NW(Q$X++*6/2)U5E6&5=<*4DTN[6-Z0S&O#\R6(#O2\XM=>KU<8JH@5"TL M)FL3-L#7;.L*X\H>3#A7),Y8?!B4!"A7H$QR6,!K["IYR?K+P)MS!/A5KIT7 MP$62;#"M709&.5P,@-Q=26CF+16&J9^:Y0&GZT62Z_I;*^:MARO&NCW6NM$R M#=5CZ*']&CIEO2_X",XC?Z6 "L:*Z2JQ!J4@.;GB'C(U0:YK9[LFQ-L.RRZ\ M"Z1B\60J)9E $,CM[D;$>9@$?O07]NDY:U&_)5:HE-L3FLK!G0K%T_5-"]B^ MZOX%E+6_E9%'$0^C+-Z/^QJF/22U%QR^VZ$DJ#<^0+^N^<[OL%<3#NA QB6= M,\I+KNUPKG=0CW0U3V,]%_2/=F@_0=X-2V\COI0",Z]Y=D?][A=B[]AW80/Q MH$:A7=$X(%UR=$TY9%Y%N)ZSI[O F@41C_:#;'C?2,UEAHF6Y"K-@%?[)+^/ MV4B?;_$JY+^@B=,K?ZUB99,4TX0E#3"&#%U1;/$V06Q,F>41M \A'CLLP=8- M(_466.874@M\S4Y=T7O&BH?ZT07[,KG]'3^#^!HT$K^:IC' BJ-;@F%S.\)0 MCF"XB*$LB%BT#Q2;]HW47&:(8T4N@PQZ=47R>1CAJ\UZKMW+,X4E?LOAQNCN MS=Q2J_G:@57D@E7>C/+V/E *; RI7DR(S;U2QE)UZ(K(>W][L6 E$2Z+WTI: M\*S02JP:M8W!-3B[I=C>B1UI6Z[@FVF0+.H1[57[3%ZX'5 =&-+DHK!Z=U4A M%W% Z".AV0#N4G;M?D8V[!SR?$86\*5TK0RI6BHR&M>,U=]MY=3IREX_U0ZB MBB3E*Y1I$:&HT".>T(>"J@<$^:H=@XK+FBR76(U^NBJT]VM,5V&\^D#)4_IP M1M:/?@Q?[%N54F$9E(T+"O1U6TBV+NP%9,X4A2,4*)>@0M.'6K'O+7G1)D"U M 2;)-6'Q[:H63A<+QF!2_'<9QG@"5H)%)]4!J&MX+\( MO!(?$)>@Z[@79PO;GI(7+#]$/Y BLV_T/!SY7DWRO9KD>ZV0[[5-OO>5Y'LU MR+]_(OTDWZM+OO=R\KTJ\KU#DS^M2?ZT)OG35LB?MDW^]"O)G]8AGVU83X_Z MT[KL3U_._K2*_>E!V#]C'Z_I/7F*;>3K*HC[LLH5]7O/5IC7[&L1KV1IO/,X M_U;,%3TB'=A%B'-XR2V4[Q- QE6_C@G/OF)?TQM*OH2Q!EP=*<2Z)G4%O&+< M"O5P'[70AU(U_G>WA82L1T5@VF.H$BQ[82D')0NL"="YZT-_?MO)>MR7)>!! M7TB<'?%SPW8.]Y)WO6-]*44_T.?!'N&M[AAX@-=7V'9T+V[M@H?VLE/'^-Z0 M)/6CO\-'XV\%;$((947H"FC)MA6LH1YJP:TG:HCG$L0TO;FY;]U7"'CC#EBP MEW) ^ '7]DN 7TR=4NP#T$.A8H)RJ,E;'TI&SE[ZH'L:W_F@2F?9I39OZ@&= MX 80^\+)!)95N[<]:)GM4\9?=!7=/) 8_ML94[B8C!YN0)QJYHHZ@Z^)/% ^ MRUI1UMR+OR8P;@RI7DR91%4I:(0=.GBB'@<;RBIAXLWO^4 54DSA8E)ZN,FS M](J9LR?I85_C<_20?)9]1&2))MX/\Q^1$!WX27K3[I#J%96Q5)6[9^A!A_:Q MO"+WU.?O+;Q[7L])!#P":5$44P,5#?@$_%PA:K8V46K*F%T15$10'NK!@Y*V MO2*U%E>F%1 +8(T^[3,K=:SP \:*22FQ!H1*3J[8A$Q-5.K:F0SC83F$=X%4 M+)[,GB03U &YW9VZWV^#![89&'@@QB913N&RQ,%IO&SH^E0.>%>=SK64F8@@ M$>K! S'6#2/U%A@^LY?5ZME==RK>X5A:BTOVB;_YMV@*\S?ESOX'4$L#!!0 M ( $."HU:D9HN1VP4 .P^ 4 ;G5S+3(P,C,P-3 S7W!R92YX;6S5 M6]MNVS@0?5]@_T'K?;9E2VVW">(6V30I@G63(,EB+R\+6J)MHA)I4')B__V2 M,IE8%$G)N123%U\TA\,S/$>WL7ST>9UGP1WF!6%TW!L-AKT TX2EA,['O571 M1T5"2._SIY]_.OJEW_^**>:HQ&DPW02_O=Q)]SOR^$9H=\/Y:83Q.'#7$Z$_-;7L+[< MU!]%_7@T6!=I3U&4X0Z3:/BZ@5]PJ2+S.LMRTXGMGS9)P_I)&K M9DSR_@]5GO096NBN^$#A*6 M;Q-_8-I47*4E#I3)@49]ZPQP5 68\3"5R>JE^E69#1X MVD**9CU49[DKX3&O,T8\T9G$QYI^S7.T0H1+Q$6^?K(@V8/T,\YRUTHR+_5= M>H=!+4-0LJ ^DO$4\W%O*"_=Q, 9YESM5Q[>%>EL=^=[30&/!=M4,C[+T-Q0 MT!I3ZV#$X&GH(]\BHC%4J3@"K**VW<.)\HLX@COV1RO&V#$-##QUNQ33<5@]ADI$I3]@Q$_$UL*A]X.E*%X P57\ .V![*7I&,GRQRJ>8&\*[PFIIFF%X,K>4T*)N M<[02]3UX4:_QG,A":'F!*%/1&D<9>?B M5G3]!]Y8E79@:E(W,%"U]A?32>Q&"J7V;^#5/J<)XTO&J_IN1)GXA*U$,9L3 MEMKW\DXC:DYH&0'5%_L4VLDE+0F59SZ"]\PM6I^GHEHR(]M?4CPG^Q9LS2=. M+%2'="NNDS>IL0BD=61WAP-3=8<5"=T%Y4)Q=8T^C^ M#N0VG8M^U-$"44<+1&_) F913[1 ]&@!R#T^%_VXHP7BCA:(WY(%S**>:('X MT0*0&W\U^B?BXR6_9??49X FRB;_+@JX^,Z"]I%^-XD6'G+GKT:^NK*]Y%>< MW9'MHS=.]1U0FP4:4. ^\)>VCQD:F;0CX'<"M9VWMSG>XT =8CT(: APY>VE M[+7[ZPQ::?CM0<7\BA4EROXE2V?[P >TJ6X @6OO*VL?!QAYM \@=P_E.>N8 M8V11WA;23X340O#4]5!OT;,^4BL(N2,H'XS-KA:,VG^]<8759HK2KDGMT-3E9<>'$436]EF8:JKK!:DF88GJHM);2HVARM587<<[OE2#YH M?[/)IRPS)+7&U&(8,7AB^LBW*&D,U4_*0.Z;7; ::D>L9M-+P&V"G.>9S MX=.OG-V7BQ.6+Q&UW_QZD;6[(0<2GOS="^MT/^1(I,T N2GVE_!PB:G@G*^H M^E7/?!3.BU'KY,# D[Y+,2VB.U)HN2%WO&Y81A)2"J]^0R7F!)F796Z /L); M /!4;BVC[>AN&:_UA=SGNN)8VA+3!%?_H)#_U>&7LUGC/KD=J!;*!X2G>^>R M6O3WY=$^@-SG,OB?%\4*\\YN<,+MGK# P3NCK<3]_&')IEWRW%[:4=A8PHG8 M(/]QOHW(%_D/[4__ U!+ 0(4 Q0 ( $."HU8(XH0>$A( $"! 3 M " 0 !B#DY+3$N:'1M4$L! A0#% @ 0X*C5D4,6S)$ P , \ ! M ( !KU< &YU